Novo Nordisk (NVO) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Study Overview: Novo Nordisk is conducting a study titled ‘Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents in Participants Treated With s.c. Liraglutide, Oral Semaglutide or s.c. Semaglutide.’ The study aims to understand how fasting and temporary stopping of GLP-1 medications affect gastric content retention in patients using liraglutide or semaglutide. This research is significant for optimizing treatment strategies for obesity.
Intervention/Treatment: The study tests three interventions: liraglutide (injected), oral semaglutide, and semaglutide (injected). These GLP-1 receptor agonists are used to manage obesity by influencing appetite and gastric emptying.
Study Design: This interventional study employs a non-randomized, parallel assignment model without masking. The primary purpose is treatment-focused, aiming to evaluate the effects of fasting and medication withholding on gastric content.
Study Timeline: The study began on November 5, 2025, with the latest update submitted on November 24, 2025. These dates mark the study’s initiation and recent progress, indicating active recruitment and ongoing data collection.
Market Implications: This study could impact Novo Nordisk’s stock performance by potentially enhancing the clinical profile of its GLP-1 medications, influencing investor sentiment positively. Competitors in the obesity treatment market may need to consider similar research to stay competitive.
The study is currently recruiting, with further details available on the ClinicalTrials portal.
To learn more about NVO’s potential, visit the Novo Nordisk drug pipeline page.